Lipocine hosts KOL event on LPCN 1154 (BRLIZIO™) for postpartum depression

Lipocine Inc.

Virtual key opinion leader event held July 9, 2025, for LPCN 1154 (BRLIZIO™).
Drug candidate targets postpartum depression; presentation replay on corporate website.
No clinical data or financial guidance disclosed in the filing.

item 8.01 item 9.01

Lipocine Inc. filing history →

Source: SEC EDGAR

accession 0001641172-25-018333

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.